The effect of immunosuppressive and immunostimulatory treatment on experimental amoebiasis

D Gold1, Y Keisari

  • 1Department of Human Microbiology, Sackler School of Medicine, Tel Aviv University, Israel.

Immunosuppressive treatments consisting of ionizing irradiation or drugs were employed in inbred and outbred mice and in golden hamsters. Following treatment, mice were challenged intracaecally or intrahepatically with virulent, axenically-grown Entamoeba histolytica. Hamsters were challenged by intraperitoneal injection of the amoebae. Many of the experimental animals died of the combined effects of treatment and challenge. Mice remained essentially refractory to infection with E. histolytica regardless of the immunosuppressive means employed. Liver infection rates in treated and control hamsters were largely similar to one another, i.e. immunosuppressive treatment had no effect on resistance to infection. Our inability to alter the susceptibility of mice and hamsters to amoebic infection by suppressing components of the immune system does not enable us to draw any clearcut conclusions as to the effect of immunosuppression on human amoebiasis. Of the various immunostimulatory materials employed in hamsters, including polysaccharides, BCG and muramyl peptides, only glucan displayed protective capacity against infection with E. histolytica, making it an effective protective agent in an extracellular parasitic infection in addition to its published effectiveness in intracellular protozoal infections. Peritoneal cells extracted from hamsters injected intraperitoneally with E. histolytica seemed capable of reducing the infectivity of virulent amoebae after coincubation in vitro, as shown by reduced infection rates in challenged hamsters. Apparently polymorphonuclear cells, which constituted the vast majority of the extracted cells 24 hours after the stimulatory injection, can, under certain conditions, diminish the infectivity of E. histolytica.

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
Amebiasis01:28

Amebiasis

Entamoeba histolytica, a protozoan parasite, is responsible for intestinal and extraintestinal amebiasis. Though a significant proportion of infections remain asymptomatic, approximately 50 million individuals annually are estimated to present with clinical disease, resulting in up to 100,000 deaths globally. The disease burden is disproportionately high in regions with lower socioeconomic status, such as parts of India, Africa, Mexico, and Latin America.Etiology and TransmissionThe infective...
Anthelminthic Agents01:15

Anthelminthic Agents

Anthelmintic drugs differ significantly from antiparasitic therapies targeting protozoa, primarily due to differences in parasite biology. Whereas most protozoal treatments act on proliferating cells, anthelmintics are typically directed against mature, nonproliferative helminths. The therapeutic approach considers the helminth's reliance on neuromuscular coordination, glucose metabolism, and microtubular integrity for survival, reproduction, and localization within the host. Most anthelmintics...
Antiprotozoal Agents01:21

Antiprotozoal Agents

Leishmaniasis is a widespread parasitic disease caused by several Leishmania species. It affects millions of people each year and remains a major public health problem in endemic regions. First-line treatment relies on pentavalent antimonials, including meglumine antimoniate and sodium stibogluconate. Even so, how these drugs work has not been fully clear, especially their interaction with parasite-specific biochemical pathways. One key target is trypanothione reductase (TR), an enzyme that...